Adaptive Biotechnologies (ADPT) closed out FY 2025 with Q4 revenue of US$71.7 million and a basic EPS loss of US$0.09, alongside net income excluding extra items of a US$13.6 million loss. This provides a clear snapshot of where the business stands after a volatile year. The company reported revenue of US$47.5 million in Q4 2024 and US$71.7 million in Q4 2025, while basic EPS moved from a loss of US$0.23 to a loss of US$0.09 over the same period. This places the focus on how far these revenue gains can carry margins toward a more sustainable footing.

See our full analysis for Adaptive Biotechnologies.

With the latest numbers on the table, the next step is to consider how this revenue trajectory and ongoing losses compare with the widely followed narratives about Adaptive Biotechnologies and what investors think needs to happen for margins to move the story forward.

Trailing Losses Still US$59.5 Million Over 12 Months

• Over the last twelve months, Adaptive Biotechnologies booked US$276.98 million in revenue and a net income loss excluding extra items of US$59.50 million, which frames Q4’s US$13.58 million loss as part of a broader pattern of negative earnings.
• What stands out against the more optimistic view is that, even with revenue expected to grow around 14.5% a year and earnings trends improving at about 8.1% a year, the business in this data set is still not forecast to be profitable over the next three years. As a result, the bullish focus on long term potential has to sit alongside a multi year period of ongoing losses.

Premium P/S Of 8.8x Versus 3.3x Peers

• The shares trade on a P/S of around 8.8x compared with about 3.3x for peers and 2.8x for the wider US Life Sciences industry, while the DCF fair value in this data is US$10.91 against a current share price of US$15.77. This highlights how much of the story is already priced in on sales alone.
• Critics highlight this premium and the DCF fair value gap as a bearish warning signal, and the numbers here back up that caution by showing that investors are paying a higher multiple despite the company still reporting a US$59.50 million trailing loss and not being projected to reach profitability within three years.

On top of that valuation gap, some investors will pay close attention to recent insider selling and share price volatility, which both sit alongside the rich P/S multiple and may help explain why cautious holders are pushing for clearer evidence of a path from US$276.98 million in annual revenue to positive earnings before paying up further. 🐻 Adaptive Biotechnologies Bear Case

Analyst Target Of US$20.43 Versus US$15.77 Today

• Analysts in this data set collectively point to a price target of about US$20.43, which is roughly 29.5% above the current US$15.77 share price, and that sits against the lower DCF fair value of US$10.91 that comes out of the modelled cash flow assumptions.
• What is interesting for the more optimistic angle is that, even though the business remains loss making on a trailing EPS of US$0.39 loss and is not projected to be profitable within three years, the combination of roughly 14.5% expected annual revenue growth and a five year trend of losses shrinking around 8.1% a year is being used in the bullish story. This is used to argue that the analyst target still has room for the shares to move higher from here.

If you want to see how those revenue forecasts and long term earnings trends are being stitched together into a full story beyond this quarter, it is worth checking the broader narrative investors are building around Adaptive Biotechnologies. 📊 Read the full Adaptive Biotechnologies Consensus Narrative.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Adaptive Biotechnologies's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

See What Else Is Out There

Adaptive Biotechnologies still reports a US$59.50 million trailing loss, trades on a premium 8.8x P/S, and is not forecast to reach profitability within three years.

If you are uneasy about paying a rich multiple for ongoing losses, you can quickly compare that picture with our 53 high quality undervalued stocks that screens for companies priced more conservatively on solid fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.